Virtual Library
Start Your Search
Y. Hu
Author of
-
+
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Track:
- Presentations: 3
- Moderators:
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
-
+
P013 - Anti-PD-1 Combination (ID 85)
00:00 - 00:00 | Author(s): Y. Hu
- Abstract
Background:
Effective treatment options are limited for advanced non-small cell lung cancer (NSCLC) patients who progressed after first-line therapy. Pronounced efficacy of anti-programmed cell death protein 1 (anti-PD-1) combination strategy was observed in first-line setting, therefore we assessed whether the addition of chemotherapy and/or bevacizumab to anti-PD-1 could improve clinical outcomes in second-line or later advanced NSCLC.
Method:
Advanced NSCLC patients treated with anti-PD-1 therapy from March 2015 to July 2017 were retrospectively screened for eligibility. First-line treatment or combined drugs beyond chemotherapy or bevacizumab were excluded. The primary objective was progression-free survival (PFS). Secondary objectives were overall response rate (ORR), disease control rate (DCR) and safety.
Results:
55 patients were included in the analysis (monotherapy, n=33; combination therapy, n=22). 90.0% of the patients have progressed after standard platinum-based chemotherapy in previous line therapies. Combination group exhibited longer PFS than monotherapy group (median, 7.5 vs 3.3 months, adjusted HR 0.32[0.16-0.65], P =0.001). 31.8% (7/22) patients in combination group achieved an objective response compared with 10.0% (3/30) in monotherapy group (P = 0.075). The DCR was 95.5% (21/22) in combination group compared with 46.7% (14/30) in monotherapy group (P<0.001). Adverse events of grade 3 or worse were occurred in 22.7% of the patients in the combination group and in 6.1% of those in monotherapy group. Most of the adverse events were manageable.
Conclusion:
Combination of anti-PD-1 plus chemotherapy and/or bevacizumab could be an effective and tolerable therapy as second-line or later treatment option for advanced NSCLC patients. -
+
P104 - Anti-PD-1 Combination Therapy in Second or Later Lines in (ID 114)
00:00 - 00:00 | Author(s): Y. Hu
- Abstract
Background:
Recent studies have indicated that anti-PD-1/PD-L1 antibodies combined with chemotherapy and/or bevacizumab could be a tolerable and effective option for patients with non-squamous NSCLC in the first line treatment. However, in second-line setting, overall response rate (ORR) of PD-1/PD-L1 checkpoint blockades used as single agent for advanced NSCLC patients who experience progression on or after platinum-based chemotherapy is limited. Therefore, we retrospectively assessed the safety and efficacy of anti-PD-1 combined with chemotherapy and/or bevacizumab as second-line treatment or beyond in patients with advanced NSCLC patients.
Method:
92 Patients of stage IIIB or IV NSCLC treated with anti-PD-1 therapy in the Cancer Center of the PLA General Hospital from January 2015 to September 2017were screened for eligibility. First-line treatment were excluded. Regimens were anti-PD-1 antibody as monotherapy or in combination with chemotherapy and/or bevacizumab. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR), disease control rate (DCR) and safety profile.
Results:
A total of 55 patients were enrolled for the study, 33 patients were received anti-PD-1 antibody monotherapy, 22 patients were received anti-PD-1 antibody plus chemotherapy and/or bevacizumab. The PFS of anti-PD-1 combination therapy was longer than that of monotherapy group (median, 7.5 vs 3.3 months, HR, 0.349, 95% CI, 0.17-0.73, P <0.0001). 7 of 22 patients (31.8%) in the combination groups achieved an objective response compared with 3 of 30 patients (10.0%) in the PD-1 antibody monotherapy group (P=0.075). 21 of 22 (95.5%) patients in the combination therapy achieved a disease control compared with 14 of 30 patients (46.7%) in the monotherapy group (P=0.000). The incidence of grade 3/4 treatment-related adverse events were 2 of 33 patients (6.1%) in monotherapy group and 5 of 22 patients (22.7%) in combination group. No treatment-related mortality was observed.
Conclusion:
Preliminary data indicated that PD-1 based combination therapy as second line treatment and beyond exhibited a promising safety profile. More importantly, PD-1 antibody plus chemotherapy and/or bevacizumab could have a longer PFS and a higher ORR and DCR. Given the relative small sample size and limitations of retrospective observational study, the strategy needs further exploration. -
+
P105 - Computational Design of IgG-like Tetra-specific Antibody Targeting EGFR/VEGF/PD-1/CTLA-4 Against NSCLC (ID 133)
00:00 - 00:00 | Author(s): Y. Hu
- Abstract
Background:
Although monoclonal antibodies (mAbs) are widely used for the treatment of cancer, the acquired resistance is one of the prime obstacles for cancer treatment and development of novel antibodies with potent anti-tumor activities and specificities is urgently needed. Due to complex diseases are often multifactorial in nature, and involve redundant or synergistic action of disease mediators or upregulation of different receptors, multi-specific antibodies with the capacity to blockade of multiple targets or binding sites are showing improved therapeutic efficacy against cancer. Although
